CME Group (NASDAQ:CME) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS

CME Group (NASDAQ:CME) posted its quarterly earnings data on Wednesday. The financial services provider reported $3.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.99 by $0.03, FiscalAI reports. CME Group had a return on equity of 16.23% and a net margin of 63.33%. The business had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.71 billion. During the same quarter last year, the firm earned $2.68 earnings per share. The business’s revenue was up 10.6% on a year-over-year basis.

Here are the key takeaways from CME Group’s conference call:

• Record third-quarter performance: Average daily volume rose 16% year over year to a record 29.4 million contracts, with double-digit growth across all six asset classes. Revenue increased 13% to $1.7 billion, adjusted EPS rose 13% to $3.02, and adjusted operating margin reached 69.4%.
• Client engagement and balance-sheet activity remained strong, with open interest reaching a record 128 million contracts at quarter-end and exceeding 133 million in October. CME said it delivered more than $100 billion per day in average margin savings, supported by growth in portfolio and cross-margining programs.
• Market data revenue grew 20% to a record $243 million, marking the 34th consecutive quarter of year-over-year growth. Management cited rising professional and retail subscriptions, data-feed demand, pricing changes, and sustained market volatility as key drivers.
• Product innovation is broadening CME’s growth opportunities, including Single Stock futures, expanded 24/7 trading, Treasury Link, and planned CME Securities Clearing. Single Stock futures generated more than 350,000 contracts and $3.5 billion in notional value shortly after launch, while Compute Futures received significant client interest but remains subject to regulatory approval.
• Management returned nearly $1 billion to shareholders through dividends and repurchases and retains flexibility for acquisitions, but emphasized a disciplined approach to M&A. Regulatory uncertainty remains around Compute Futures, 24/7 oil trading, and perpetual contracts, while management stressed that broader 24/7 markets may require supporting banking and clearing infrastructure.

CME Group Stock Performance

NASDAQ:CME opened at $305.98 on Friday. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.13. The firm’s fifty day simple moving average is $276.89 and its 200 day simple moving average is $270.49. The firm has a market capitalization of $110.02 billion, a PE ratio of 25.95, a PEG ratio of 3.81 and a beta of 0.24. CME Group has a 1 year low of $218.31 and a 1 year high of $329.16.

CME Group Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 25th. Stockholders of record on Wednesday, September 9th were given a $1.30 dividend. The ex-dividend date of this dividend was Wednesday, September 9th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 1.7%. CME Group’s dividend payout ratio (DPR) is currently 44.11%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on CME. TD Cowen upped their target price on shares of CME Group from $292.00 to $300.00 and gave the company a “buy” rating in a research note on Monday, October 5th. Wells Fargo & Company boosted their price target on shares of CME Group from $315.00 to $333.00 and gave the stock an “overweight” rating in a research report on Thursday. The Goldman Sachs Group reduced their price objective on shares of CME Group from $267.00 to $245.00 and set a “sell” rating for the company in a research report on Tuesday, June 30th. JPMorgan Chase & Co. raised CME Group from an “underweight” rating to an “overweight” rating and set a $367.00 price target on the stock in a research note on Thursday. Finally, Bank of America raised their price objective on shares of CME Group from $226.00 to $230.00 and gave the stock an “underperform” rating in a research note on Thursday, July 23rd. Ten analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, CME Group presently has a consensus rating of “Hold” and an average price target of $313.29.

Insider Activity at CME Group

In related news, Director William R. Shepard acquired 293 shares of the firm’s stock in a transaction on Friday, September 25th. The shares were purchased at an average price of $268.76 per share, with a total value of $78,746.68. Following the acquisition, the director directly owned 263,289 shares in the company, valued at $70,761,551.64. The trade was a 0.11% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director Elizabeth A. Cook sold 500 shares of the business’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $280.11, for a total value of $140,055.00. Following the completion of the transaction, the director directly owned 17,916 shares of the company’s stock, valued at approximately $5,018,450.76. The trade was a 2.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 15,900 shares of company stock worth $4,377,655. Insiders own 0.30% of the company’s stock.

More CME Group News

Here are the key news stories impacting CME Group this week:

• Positive Sentiment: Record volumes support earnings growth: Average daily volume reached a quarterly record of 29.4 million contracts, while non-U.S. volume hit 9 million. Higher derivatives activity drove clearing and transaction-fee revenue to $1.4 billion, and market-data revenue rose 20% to a record $243 million. CME Group Q3 earnings
• Positive Sentiment: Strong profitability and shareholder returns: CME reported approximately $1.04 billion in net income and returned nearly $1 billion through dividends and share repurchases. The results reinforce the company’s high-margin business model and cash-generation profile. CME Group financial results
• Positive Sentiment: Analyst support and new growth initiatives: JPMorgan upgraded CME from “underweight” to “overweight” with a $367 price target. CME also plans to launch CME Securities Clearing on December 7, while continued crypto-derivatives activity and new token-index products offer additional growth potential, although crypto revenue is not reported separately. CME Securities Clearing launch
• Neutral Sentiment: Analyst opinions remain mixed: UBS raised its target from $270 to $310 but retained a “neutral” rating, indicating that valuation may limit further gains after the recent advance. UBS CME rating
• Negative Sentiment: Expense and insider-selling concerns: Investors initially focused on higher-than-expected expenses despite the earnings beat. Director Martin Gepsman sold 400 shares for $121,000, though the transaction reduced his holdings by only 1.56% and therefore appears to be a limited signal. CME insider sale

About CME Group

CME Group Inc operates global derivatives marketplaces that provide trading, clearing and settlement services for futures and options contracts. Its products cover major asset classes, including interest rates, equity indexes, foreign currencies, agricultural commodities, energy and metals. The company also provides market data, benchmark information and related services used by financial institutions, corporations, producers, investors and other market participants.

CME Group’s exchange portfolio includes CME, the Chicago Board of Trade, the New York Mercantile Exchange and COMEX.